Repare Therapeutics RPTX 深 沪
等待开盘 10-25 09:30:00 美东时间
1.96
+0.030
+1.55%
华盛通- 最 高1.9696
- 今 开1.93
- 成交量 20.67万股
- 最 低 1.91
- 昨 收 1.93
- 总市值 8420.00万
- 52周最高 4.0695
- 市盈率 静 --
- 换手率 0.48%
- 52周最低 0.89
- 委 比 -77.38%
- 总股本 4295.92万
- 历史最高 46.44
- 量 比 0.83
- 振 幅 3.09%
- 历史最低 0.89
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
RASTherapeutics宣布将于10月20日发布其合作伙伴上海杰优医药开发的RPT904在慢性自发性荨麻疹患者中进行的II期临床试验顶线数据，并举行网络研讨会，提供电话和网络接入方式。公司简介及联系方式随附。
10-19 12:00
Repare Therapeutics To Share Initial Topline Safety, Tolerability And Early Efficacy Data From Phase 1 LIONS Trial In Poster Presentation At AACR-NCI-EORTC International Conference 2025
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy data from the Phase 1
10-14 04:06
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
RAPT Therapeutics received FDA clearance to initiate a Phase 2b trial for RPT904, a long-acting anti-IgE antibody, targeting food allergies. The trial will compare dosing every 8 or 12 weeks. RAPT expects to start the trial by year-end and anticipates data from Jeyou's Phase 2 studies in chronic urticaria and asthma. RPT904 aims to inhibit IgE, with better pharmacokinetics than first-gen anti-IgE drugs.
09-29 09:00
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rapport Therapeutics announced that its management will participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025. The company, focused on developing precision medicines for neurological and psychiatric disorders, will host a fireside chat during the virtual event. Investors can access the webcast on the company’s website. Rapport’s RAP technology platform enables the creation of targeted sma...
09-11 20:05
Rapport Announces Proposed Public Offering of Common Stock
Rapport Therapeutics is conducting a $250 million underwritten public offering of its common stock, with an option for underwriters to purchase an additional $37.5 million. The offering is subject to market conditions and has been filed with the SEC under a shelf registration statement. Rapport Therapeutics focuses on developing small molecule precision medicines for neurological and psychiatric disorders, utilizing its RAP technology platform to...
09-08 20:05
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
Rapport Therapeutics将举行电话会议和网络直播，于9月8日上午8点ET，公布RAP-219治疗难治性局灶性癫痫的IIa期顶线结果。公司聚焦神经及精神疾病精准药物，RAP技术基于受体蛋白，使药物如RAP-219精准作用于大脑特定区域，用于治疗癫痫、双相情感障碍和神经痛等。
09-05 20:05
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
RAPT Therapeutics reported Q2 and H1 2025 financial results, highlighting a net loss of $17.6 million for Q2 and $34.8 million for H1, compared to $27.7 million and $58.2 million in 2024. R&D expenses decreased by $10.3 million and $23.0 million, while G&A expenses increased slightly. The company strengthened its team and pipeline, with plans to initiate a Phase 2b trial for RPT904 in food allergy later this year and report topline results from J...
08-07 12:00
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics reported that the Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled and expects topline results in September 2025. Additionally, the Phase 2 trial for bipolar mania is ongoing with results anticipated in the first half of 2027. The company ended Q2 2025 with $260.4 million in cash, supporting operations through 2026. Second-quarter net loss was $26.7 million, with R&D and G&A expenses increas...
08-07 11:00
reAlpha Tech Corp. Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
reAlpha Tech Corp. announced the purchase and sale of 14,285,718 shares of its common stock at $0.35 per share in a registered direct offering under Nasdaq rules. Concurrently, the company will issue unregistered warrants for up to 14,285,718 shares with an exercise price of $0.35 per share, exercisable immediately and expiring in five years. The offering is expected to close on July 22, 2025, subject to customary closing conditions. H.C. Wainwri...
07-21 20:30
Repare Therapeutics shares are trading higher after the company entered a licensing agreement with Debiopharm for Lunresertib.
Repare Therapeutics shares are trading higher after the company entered a licen...
07-16 04:11
